FY2017 EPS Estimates for Amgen, Inc. Raised by William Blair (AMGN)

Amgen, Inc. (NASDAQ:AMGN) – Stock analysts at William Blair increased their FY2017 EPS estimates for Amgen in a research note issued to investors on Monday. William Blair analyst M. Phipps now anticipates that the medical research company will post earnings of $12.65 per share for the year, up from their prior estimate of $12.41. William Blair also issued estimates for Amgen’s Q4 2017 earnings at $2.96 EPS, Q1 2018 earnings at $3.27 EPS, Q2 2018 earnings at $3.08 EPS, Q3 2018 earnings at $3.18 EPS, Q4 2018 earnings at $3.13 EPS and FY2018 earnings at $12.66 EPS.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. Amgen’s revenue was down .7% on a year-over-year basis. During the same period in the prior year, the business posted $3.02 EPS.

A number of other brokerages have also recently commented on AMGN. Royal Bank Of Canada began coverage on Amgen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price target for the company. Bank of America upped their price target on Amgen to $210.00 and gave the company a “buy” rating in a research note on Thursday, October 5th. Oppenheimer reiterated a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research report on Friday, October 6th. Mizuho reiterated a “buy” rating and issued a $198.00 price objective on shares of Amgen in a research report on Friday, October 6th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $196.00 price objective (up from $189.00) on shares of Amgen in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. Amgen has a consensus rating of “Hold” and a consensus target price of $190.22.

Shares of Amgen (NASDAQ AMGN) opened at $176.22 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. The company has a market capitalization of $129,712.96, a PE ratio of 14.20, a PEG ratio of 2.59 and a beta of 1.36. Amgen has a 52 week low of $138.83 and a 52 week high of $191.10.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.61%. The ex-dividend date is Thursday, November 16th. Amgen’s payout ratio is 41.63%.

Amgen announced that its board has authorized a stock repurchase plan on Wednesday, October 25th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,050 shares of company stock worth $1,239,673 in the last quarter. Company insiders own 0.19% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Shelton Capital Management grew its holdings in shares of Amgen by 4.0% during the 3rd quarter. Shelton Capital Management now owns 72,293 shares of the medical research company’s stock worth $13,479,000 after purchasing an additional 2,809 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in shares of Amgen during the 3rd quarter worth $4,988,000. GSA Capital Partners LLP acquired a new stake in shares of Amgen during the 3rd quarter worth $682,000. Coastline Trust Co grew its holdings in shares of Amgen by 18.1% during the 3rd quarter. Coastline Trust Co now owns 13,345 shares of the medical research company’s stock worth $2,488,000 after purchasing an additional 2,045 shares in the last quarter. Finally, Archford Capital Strategies LLC grew its holdings in shares of Amgen by 28.1% during the 3rd quarter. Archford Capital Strategies LLC now owns 11,691 shares of the medical research company’s stock worth $2,180,000 after purchasing an additional 2,567 shares in the last quarter. 78.38% of the stock is currently owned by institutional investors.

WARNING: “FY2017 EPS Estimates for Amgen, Inc. Raised by William Blair (AMGN)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://ledgergazette.com/2017/12/07/fy2017-eps-estimates-for-amgen-inc-raised-by-william-blair-amgn.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply